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OBJECTIVE: To describe the clinicopathological characteristics of patients with upper urinary tract transitional cell carcinomas 
who are treated surgically and to analyze the occurrence of bladder tumors as well as the development of metastases outside the 
urinary tract. 
MATERIALS AND METHODS: The study comprised a retrospective analysis of 25 patients treated between February 1994 and 
August 2006. The variables analyzed were: patient age, gender, and clinical presentation; diagnostic methods; pathologic charac-
teristics at the primary site of the tumor (pelvis or ureter); tumor stage and grade; and presence of carcinoma in situ, microvascular 
invasion and squamous differentiation. The Kaplan-Meier method and the Log-Rank test were used for statistical analysis of blad-
der recurrence-free survival. 
RESULTS: Eighty-four percent of patients were male, and macroscopic hematuria was the most common clinical presentation. The 
majority of cases (56%) were infiltrative (T2-T3) and high-grade (76%) tumors. Synchronous or metachronous bladder tumors were 
found in 72% of cases. Five (20%) patients had a history of bladder tumor before the diagnosis of upper urinary tract transitional 
cell carcinomas. The mean follow-up period was 36 months (range: 1.5 to 156). During the follow-up period, eleven (44%) patients 
developed bladder tumors. After five years, the probability of being free of bladder tumor recurrence was 40%. No pathological 
variable was predictive for bladder tumor recurrence. Four patients presented disease recurrence outside the urinary tract.
CONCLUSIONS: The presence of metachronous bladder tumors is more often observed after the diagnosis of upper urinary tract 
transitional cell carcinomas. All of these patients should undergo rigorous follow-up during the postoperative period. Only patients 
with infiltrative and high-grade tumors developed metastases outside the urinary tract.
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INTRODUCTION
Upper urinary tract transitional cell carcinomas (UUT-
TCC) are rare lesions. They account for 5% of all urothelial 
tumors and 10% of all renal tumors.1 As North American 
statistics estimate that there will be 38,890 new cases of 
kidney and renal pelvis tumors in 2006, this represents 
only about 3,889 new cases of renal pelvis tumors during 
the current year.2 Primary ureteral tumors are even rarer 
and are found 3 to 4 times less frequently than renal pelvis 
tumors.3 Nephroureterectomy with bladder cuff removal is 
considered the standard treatment for UUTTCC;4 however, 
these tumors often behave aggressively, and local failure 
rates are high even after radical surgical treatment.1 Due to 
its inherent rarity, most of the clinical-pathological charac-
teristics of UUTTCC are not well known, and a better un-
derstanding of these characteristics would allow for earlier 
diagnosis and more efficient treatment for the patients. One 
of the most important characteristics of surgically-treated 
urothelial carcinomas is the ongoing risk of developing 
tumors in the remnant urothelium during the follow-up 224
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period.5,6 In addition, the best follow-up protocol has not, 
thus far, been defined.
In the present study, the authors describe the main 
clinicopathological characteristics of patients with UUTTCC 
who are treated surgically, and analyze the occurrence of 
synchronous and metachronous bladder tumors as well as the 
development of metastases outside the urinary tract.
MATERIALS AND METHODS
The study comprised a retrospective analysis of 25 pa-
tients with UUTTCC treated between February 1994 and 
August 2006. Patients with unavailable clinical and patho-
logic data, as well as patients with other histologic types of 
tumors, were excluded from the analysis. All information 
was obtained by a review of the medical records.
Regarding preoperative image analysis, an ultrasound 
(USG) of the urinary tract was performed in 17 (68%) cases, 
excretory urography in 14 (56%) cases, and abdominal 
computed tomography (CT) in 22 (88%) cases. A retrograde 
pyelogram was performed in eight (32%) patients at the time 
of surgery to clarify the diagnosis. 
All surgical procedures were performed by only one sur-
geon (M.S.). Twenty-one patients (84%) underwent a classic 
nephroureterectomy with bladder cuff removal. Four patients 
underwent renal sparing surgery, including two patients of 
advanced age who had small primary ureteral tumors and 
underwent partial ureterectomy, one patient with a right 
renal agenesis who underwent an inferior pielectomy, and 
one patient that presented with bilateral UUTTCC and was 
found to have panurothelial disease. This patient underwent 
a cystectomy with bilateral ureterectomy. Dissection of the 
regional lymph nodes was performed only in patients who 
had enlarged nodes based on preoperative image analysis 
or intraoperative examination. The follow-up schedule was 
the same for all patients; they were seen every four months 
for the first year and semiannually thereafter. Office visits 
consisted of physical examination, serum chemistry, and uri-
nalysis with urinary cytology. Diagnostic CT imaging of the 
abdomen and pelvis was performed on the same schedule, 
and cystoscopy was performed on a semiannual basis.
The variables analyzed were: patient age, gender, and 
clinical presentation; diagnostic methods; pathologic char-
acteristics at the primary site of the tumor (pelvis or ureter); 
tumor stage and grade; and the presence of carcinoma in 
situ, microvascular invasion (MVI), and squamous differ-
entiation. We also analyzed the occurrence of synchronous 
or metachronous bladder tumors and the characteristics of 
these lesions. All superficial bladder tumors were treated 
with intravesical Bacillus Calmette-Guerin vaccine if they 
had one of following characteristics: high grade, stage of T1, 
recurrence, multiple lesions, or association with carcinoma 
in situ.
The pathological stage was defined according to the 
UICC classification,7 and tumor grade was based on the 
2004 World Health Organization system.8 All pathologic 
analyses were performed by a single pathologist (K.R.L.). 
The Kaplan-Meier method and the Log Rank test were used 
for analysis of bladder recurrence-free survival. Statistical 
significance was set as p ≤ 0.05. Statistical analysis was 
performed using SPSS 12.0 for Windows.
RESULTS
The mean patient age was 64.4 years (range: 39 to 85 
years). There were 21 men and 4 women. At the time of 
diagnosis, 20 (80%) patients presented with macroscopic 
hematuria as the main complaint. Among the remaining five 
patients, one had urinary retention due to an enlarged pros-
tate, two had irritative lower urinary tract symptoms, one had 
lumbar pain and one had only microscopic hematuria. Micro-
scopic hematuria was found in all cases. Overall, flank pain 
was present in four (16%) patients. The length of time from 
the beginning of symptoms to definitive diagnosis varied 
from two days to nine months among the patients. Regard-
ing image analysis, the USG of the urinary tract suggested 
the correct diagnosis in 5/17 (29.4%) cases, the excretory 
urography in 14/14 (100%) cases, and the abdominal CT in 
19/22 (86.3%) cases. 
Table 1 describes the main clinicopathological findings 
for the 25 UUTTCC. In 21 (84%) cases, tumors were located 
in the renal pelvis. Tumors were located on the right side in 
14 (56%) cases. There was only one synchronous ureteral 
tumor and no metachronous tumors in the contralateral upper 
tract. The majority of cases (56%) were infiltrative (T2-T3) 
and high-grade (76%) tumors. In situ carcinoma was found 
in 12%, MVI in 36%, and squamous differentiation in 16% 
of cases. No patient presented with positive lymph nodes.
Synchronous or metachronous bladder tumors were 
found in 72% of cases. Five (20%) patients had a history of 
bladder tumors before the diagnosis of UUTTCC. The length 
of time from the diagnosis of the first bladder tumor to the 
diagnosis of UUTTCC varied from 10 months to 12 years 
(mean of 72 months). All of these cases presented superfi-
cial (Ta-T1) grade 1 to 3 bladder carcinomas. Two patients 
were found to have bladder tumors at the time of UUTTCC 
diagnosis: one had a Ta grade 3 tumor and the other had a 
T2 grade 4 tumor. The latter patient was an 85-year old man 
who was not considered for radical cystectomy due to his 
advanced age. 
The mean follow-up period was 36 months (range: 1.5 
to 156 months). During the follow-up period, eleven (44%) 225
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patients developed bladder tumors. The mean length of 
time for diagnosis of bladder tumor was 19 months (4 to 
60 months). The probability of being free of bladder tumor 
recurrence was 40% when patients were followed-up for 
at least five years (Figure 1). All of the cases but one were 
superficial (Ta-T1) grade 1 to 3 tumors, and only one had an 
associated in situ carcinoma. Using the Log-Rank test, we 
found that no clinicopathological variable was associated 
with an increased risk of bladder tumor recurrence. Three 
patients underwent radical cystectomy: one 12 years before 
the diagnosis of UUTTCC, one simultaneously with the di-
agnosis of UUTTCC (described above), and one 15 months 
after a right nephroureterectomy for a T1 grade 3 bladder 
tumor (Table 2).
Four patients presented disease recurrence outside the 
urinary tract. Two patients developed pelvic masses 10 and 
30 months after treatment, respectively, and two developed 
pulmonary metastases 8 and 33 months after treatment, re-
spectively. The first two patients had presented a T1 grade 
3 and T3 grade 3 UUTTCC, and the pelvic masses were 
surgically removed. The patients underwent adjuvant che-
motherapy. The latter two patients presented with infiltrative 
grade 4 UUTTCC. Pulmonary metastases were treated with 
chemotherapy, but the patients died a few months later.
Table 1 - Clinicopathological characteristics of the 25 UUT-
TCC
Median Age (Min – Max) 64 (39 – 85)
Gender
Male 21 (84.0%)
Female 4 (16.0%)
Clinical findings
Macroscopic hematuria  20 (80%) 
Flank pain  4 (16%) 
No symptoms 1 (4%)
Side of tumor
Right  14 (56%) 
Left 11 (44%)
Primary site
Pelvis  21 (84%) 
Ureter 4 (16%)
Stage
Ta 2 (8.0%)
T1 9 (36.0%)
T2 3 (12.0%)
T3 11 (44.0%)
Grade
Low 6 (24.0%)
High 19 (76.0%)
Squamous differentiation
Yes 4 (16.0%)
No 21 (84.0%)
MVI
Yes 9 (36.0%)
No 16 (64.0%)
Carcinoma in situ
Yes 3 (12.0%)
No 22 (88.0%)
Table 2 - Characteristics of synchronous and metachronous 
bladder tumors
Characteristics n
Patients with bladder tumors 18 (72%)
Occurrence of the bladder tumor
Before 5 (mean 72 months earlier)
Simultaneous 2
After 11 (mean 19 months later)
Pathological characteristics of the 
bladder tumors
Stage
Ta 12
T1 5
T2 1
Grade
Low 9
High 9
Carcinoma in situ 1
Cystectomy 3
Before 1 (12 years earlier)
Simultaneous 1
After 1 (15 months later)
Figure 1 - Bladder tumor recurrence-free survival after treatment for UUT-
TCC226
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DISCUSSION
In the present study, the authors describe important 
clinicopathological characteristics of UUTTCC. Eighty-four 
percent of patients were male, and macroscopic hematuria 
was the most common clinical presentation. The most ac-
curate preoperative image analysis was excretory urography, 
followed by CT and USG. Currently, multidetector CT scans 
are more accurate than the older ones used in this series; 
thus, CT will likely reach the same accuracy as excretory 
urography in the near future.9 Most of the tumors in the pres-
ent series showed aggressive pathological characteristics, 
as 56% were infiltrative (T2-T3) and 76% were high-grade 
tumors. In the series assessed by Park et al,1 86 patients with 
UUTTCC were analyzed and hematuria and flank pain were 
found in 77.9% and 16.3% of cases, respectively. Infiltrative 
tumors comprised 57% of cases, and 93% of cases were 
grade 2 or 3 tumors. In the present study, pelvis tumors were 
five times more common than ureteral tumors. All four cases 
of ureteral tumors were superficial lesions, and two of them 
were low-grade lesions. Because we examined only four 
primary ureteral tumors, an accurate comparison with pelvis 
tumors was not possible. Usually, cases of ureteral tumors 
present higher rates of infiltrative and high-grade lesions and 
show significantly lower disease-free survival than those of 
pelvis tumors.1 These characteristics are probably due to the 
thin muscle layer of the renal pelvis and ureter.
MVI and squamous differentiation are two less well de-
scribed pathological characteristics of UUTTCC. Recently, 
Kikuchi et al10 reported that in multivariate analysis of MVI, 
pathological stage and tumor grade were independent predic-
tors of disease-specific survival. They stratified patients into 
three risk groups based on these characteristics. With regard 
to squamous differentiation, Antunes et al. showed that this 
characteristic is an independent prognostic factor for blad-
der cancer-specific survival11. In the present study, MVI and 
squamous differentiation were present in 36% and 16% of 
cases, respectively.
The occurrence of synchronous or metachronous bladder 
tumors was found in 72% of cases. Five patients had a histo-
ry of bladder tumors prior to the diagnosis of UUTTCC. All 
cases were superficial bladder tumors (Ta - T1) and the mean 
time to diagnosis of UUTTCC was 72 months. The propor-
tion of patients who develop upper urinary tract tumors after 
the diagnosis and treatment of superficial bladder tumors has 
been reported as only 0.002% to 2.4% in one series follow-
ing surveillance intervals of 5 to 13 years.12 According to 
Canales et al.,6 the risk of upper urinary tract recurrence is 
increased even in patients with Ta bladder cancer. A review 
of 375 patients who underwent resection of a stage Ta tumor 
with a median follow-up of 6 years showed that UUTTCC 
had developed in 13 patients (3.4%) an average of 22 months 
after their initial bladder tumor. A high-risk group consisting 
of patients who had two or more bladder recurrences within 
12 months of each other was at a 4.5-fold greater risk of 
UUTTCC. A low incidence of UUTTCC was also observed 
for patients submitted to radical cystectomy according to 
Sanderson et al., who examined more than 1000 patients.13
The majority of cases in the present series developed 
bladder tumors after treatment for UUTTCC, all of which 
were also superficial bladder lesions. Among the 11 cases 
of UUTTCC who developed bladder tumors, six were infil-
trative and eight were high-grade lesions. No clinicopatho-
logical variable was associated with an increased risk of 
bladder recurrence. In the series assessed by Holmang and 
Johansson,14 bladder cancer was present in 83% of patients 
with bilateral UUTTCC compared to 31% among those with 
unilateral UUTTCC. Interestingly, Raman et al. found that 
more than 90% of cases were superficial bladder cancers, 
and the majority of these were low-grade. In this series, the 
only predictor of the subsequent development of a bladder 
tumor was a history of bladder cancer.15 This study is part of 
the general trend in our service to survey diagnosis and risk 
factors of urologic neoplasias.16
No patient in the present series developed metachro-
nous tumors in the contralateral upper urinary tract during 
the follow-up period. The risk of metachronous UUTTCC 
among 768 patients with UUTTCC diagnosed in a 28-year 
period was 3.1% after a median follow-up of 46 months. 
The projected incidence after initial UUTTCC diagnosis was 
2.7%, 5.8% and 6.5% at 5, 10 and 15 years, respectively14. 
Only one patient in the present series presented bilateral 
disease. This patient was a 59-year-old female with a his-
tory of recurrent superficial bladder cancer. Since the initial 
diagnosis twelve years earlier, she presented 12 recurrences 
in the bladder, all of which were treated with transurethral 
resection and adjuvant therapy. Pathology samples had al-
ways shown Ta grade 1 transitional cell carcinoma. At the 
last recurrence, she presented a papillary grade 3 transitional 
cell carcinoma. At this time, an intravenous urography and 
ureteroscopy revealed lesions in both ureters. The patient 
underwent a radical cystectomy with total right ureterectomy 
and distal left ureterectomy. Orthotopic ileal neobladder 
reconstruction was performed, with the distal ileum detubu-
lized and rearranged into a U shape. Both ends of the “U” 
shaped ileum were kept long enough to perform a pyelo-ileal 
anastomosis and a proximal uretero-ileal anastomosis at the 
right and left sides, respectively17. 
Three patients underwent radical cystectomy during the 
study period: one 12 years before UUTTCC diagnosis, one 
simultaneously with UUTTCC diagnosis (described above), 
and the other 15 months after a right nephroureterectomy. In 227
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the series performed by Akkad et al.,5 the risk of developing 
an UUTTCC after radical cystectomy was 4.7% after a 56 
month follow-up period. All patients who had secondary 
UUTTCC had undergone cystectomy for multifocal or re-
current TCC.
All four patients who developed metastases outside the 
urinary tract had high-grade tumors, and three of them had 
infiltrative (T2-T3) tumors. An analysis of the prognostic 
factors for 5-year recurrence-free survival in 72 patients 
treated for UUTTCC revealed that stage, grade and tumor 
location in the urothelium were independent prognostic 
variables based on multivariate analysis.18 Based on these 
findings, one might consider treating low-grade superficial 
tumors conservatively. However, we cannot comment on this 
issue due to our small sample size. Furthermore, this remains 
a controversial issue in the literature, with higher recurrence 
rates and lower cancer-specific survival with conservative 
treatment.19
Finally, it is important to address the retrospective design 
of our study, as well as the small sample size due to the rarity 
of this cancer. However, we can conclude that most UUT-
TCC are infiltrative and high-grade lesions. The presence of 
metachronous bladder tumors are more often observed after 
UUTTCC diagnosis, and the great majority of these tumors 
are superficial lesions that can appear several years after the 
diagnosis of UUTTCC. No clinicopathological variable is 
predictive of bladder recurrence; thus, all of these patients 
should undergo rigorous follow-up with urinary cytology, 
USG and cystoscopic examinations during the postopera-
tive period. In our study, only patients with infiltrative and 
high-grade tumors developed metastases outside the urinary 
tract.
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